Dissolution testing of tablets within and beyond expiration date with olanzapine as pharmaceutical ingredient

Autor

  • Karol Kluczek Doctorate of Department of Hospital Pharmacy, Faculty of Pharmacy, Medical University of Łódź, Poland Autor
  • Sebastian Czajka Doctorate of Department of Hospital Pharmacy, Faculty of Pharmacy, Medical University of Łódź, Poland Autor
  • Andrzej Stańczak Head of Department of Hospital Pharmacy, Faculty of Pharmacy, Medical University of Łódź, Poland Autor

DOI:

https://doi.org/10.12923/j.2084-980X/25.1/a.16

Słowa kluczowe:

olanzapine, dissolution test, HPLC, expiration date of drug product

Abstrakt

The expiration date is a guarantee from the manufacturer that a drug product will remain chemically stable - and thus maintain its full potency and safety - prior to that date. Authors of this study have checked whether tested drug product has a similar dissolution profile beyond and within expiration date. In this paper, dissolution study of Zyprexa (Olanzapine as an Active Pharmaceutical Ingredient) 10 mg tablets was conducted in three different mediums, in the same way as comparison in-vitro and in-vivo tests during investigation of bioavailability and bioequivalence at clinical trials phase. Obtained results demonstrated that dissolution profiles of tested and reference product are essentially similar, which was statistically confirmed by means of similarity factor.

Bibliografia

1. Dressman J., Krämer J., Pharmaceutical Dissolution Testing. Taylor & Francis Group, p. 356-357, 2005.

2. European Medicines Agency, Olanzapine Neopharma: European Public Assessment Reports – Scientific Discussion, 2007.

3. Gohe M. C., et al. Assessment of Similarity Factor Using Different Weighting Approaches. Dissolution Technol., 12 (4), p. 22-26, 2005.

4. Gohel M. C. and Panchal M. K.: Dissolution Technol., 7 (1), p. 1-5, 2002.

5. Guidance for Industry – Dissolution Testing of Immediate Release Solid Oral Doasage Forms. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S. Government Printing Office: Washington, DC, 1997.

6. Guidance for Industry - Waiver of in Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000.

7. Guideline on the investigation of bioequivalence, CPMP/EWP/QWP/1401/98 Rev. 1/ Corr, EMEA, 2010.

8. Lyon R.C., et al.: J. Pharm Sci., 95, p. 1549, 2006

9. Jasińska M., et al.: Acta Pol. Pharm. Drug Res., 66, p. 703-707, 2009

10. Mi-chia M., Ru-pyng L. and Jen-pei L., Statistical evaluations of dissolution similarity, Stat Sinica, 9, p. 1011-1027, 1999.

11. Pre-conference Symposium: Dissolution Testing. Informa Lifesciences,

Hungary, 2007.

12. Sathirakul K., et al.: B J Clin Pharmacol., 56, p. 184-187, 2003.

Opublikowane

2012-03-30